Wu Xiaolei, Yang Zhangzhong, Zou Jinjun, Gao Huile, Shao Zhenhua, Li Chuanzhou, Lei Peng
Department of Neurology and State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of Pharmacy, Sichuan University, Chengdu, China.
Signal Transduct Target Ther. 2025 May 7;10(1):146. doi: 10.1038/s41392-025-02179-x.
Neurodegenerative diseases (e.g., Alzheimer's, Parkinson's, Huntington's disease, and Amyotrophic Lateral Sclerosis) are major health threats for the aging population and their prevalences continue to rise with the increasing of life expectancy. Although progress has been made, there is still a lack of effective cures to date, and an in-depth understanding of the molecular and cellular mechanisms of these neurodegenerative diseases is imperative for drug development. Protein phosphorylation, regulated by protein kinases and protein phosphatases, participates in most cellular events, whereas aberrant phosphorylation manifests as a main cause of diseases. As evidenced by pharmacological and pathological studies, protein kinases are proven to be promising therapeutic targets for various diseases, such as cancers, central nervous system disorders, and cardiovascular diseases. The mechanisms of protein phosphatases in pathophysiology have been extensively reviewed, but a systematic summary of the role of protein kinases in the nervous system is lacking. Here, we focus on the involvement of protein kinases in neurodegenerative diseases, by summarizing the current knowledge on the major kinases and related regulatory signal transduction pathways implicated in diseases. We further discuss the role and complexity of kinase-kinase networks in the pathogenesis of neurodegenerative diseases, illustrate the advances of clinical applications of protein kinase inhibitors or novel kinase-targeted therapeutic strategies (such as antisense oligonucleotides and gene therapy) for effective prevention and early intervention.
神经退行性疾病(如阿尔茨海默病、帕金森病、亨廷顿病和肌萎缩侧索硬化症)是老龄人口面临的主要健康威胁,且随着预期寿命的增加,其患病率持续上升。尽管已取得进展,但迄今为止仍缺乏有效的治疗方法,深入了解这些神经退行性疾病的分子和细胞机制对于药物开发至关重要。由蛋白激酶和蛋白磷酸酶调节的蛋白质磷酸化参与了大多数细胞活动,而异常磷酸化则是疾病的主要原因。药理学和病理学研究表明,蛋白激酶被证明是各种疾病(如癌症、中枢神经系统疾病和心血管疾病)的有前景的治疗靶点。关于蛋白磷酸酶在病理生理学中的机制已有广泛综述,但缺乏对蛋白激酶在神经系统中作用的系统总结。在此,我们通过总结目前关于与疾病相关的主要激酶和相关调节信号转导途径的知识,聚焦于蛋白激酶在神经退行性疾病中的参与情况。我们进一步讨论激酶 - 激酶网络在神经退行性疾病发病机制中的作用和复杂性,阐述蛋白激酶抑制剂或新型激酶靶向治疗策略(如反义寡核苷酸和基因治疗)在有效预防和早期干预方面临床应用的进展。